您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Cetuximab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cetuximab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:205923-56-4
包装与价格:
包装价格(元)
1mg电议
5mg电议
25mg电议
50mg电议

产品名称
西妥昔单抗
C225
产品介绍
Cetuximab (C225) 是一种人源 IgG1 单克隆抗体,能够抑制EGFR,SPR 方法测得 Cetuximab 对EGFRKd值为 0.201 nM;Cetuximab 具有高效的抗肿瘤作用。
生物活性

Cetuximab (C225) is a humanIgG1monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with aKdof 0.201 nM forEGFRby SPR. Cetuximab has potent antitumor activity[1].

IC50& Target[1]

Soluble EGFR

0.201 nM (Kd)

EGFR

0.147 nM (Kd, Fixed A431 cells)

体外研究
(In Vitro)

Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kdof 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a Kdof 0.147 nM for EGFR in fixed A431 cells by ELISA[1]. Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G0/G1arrest, induces apoptosis, and reduces Rb, p27KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells[3].

体内研究
(In Vivo)

Cetuximab (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab treatment significantly reduces the expression of EGFR, pEGFR and Ki67. The MCT1 and GLUT1 expression is significantly decreased in the Cetuximab-treated groups of both cell lines but differences are more pronounced in UT-SCC-14 xenografts[2].

Clinical Trial
分子量

145543.35

性状

Liquid

CAS 号

205923-56-4

中文名称

西妥昔单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.